Citi Pharma secures $109,500 payment for first nutraceutical shipment to US

September 20, 2024 (MLN): Citi Pharma Ltd (PSX: CPHL) has made a significant milestone by becoming Pakistan's first exporter of nutraceutical products to the USA, receiving a payment of $109,500 for its initial shipment.

The company, which is the largest API manufacturer in Pakistan, has announced that its nutraceutical products have received FDA approval, allowing for a formal launch in September 2024.

The approved product categories include:

• Fertility
• Weight management
• Stress and mood boosters
• Hair and skin care
• Joint and muscle pain relief

This approval underscores Citi Pharma's adherence to rigorous international quality standards, allowing the company to enter the highly competitive U.S. market by exporting the finished nutraceutical products

"CPHL offers an extensive section of API, Formulations, Nutraceutical product line for both Local and Global customers. Their product lines Tablets, Capsules, Powder Sachets, Syrups, Ointments and Gels, Injections, Infusion and Sus", the company stated in its latest filing.

What sets Citi Pharma Ltd apart is its unwavering commitment to quality and purity. All products are crafted to best of product line, ensuring the highest standard of care for life.

Under the leadership of CEO Mr. Rizwan, the company has positioned itself as an industry leader, driven by a vision to deliver top-quality products.

The financial implications are significant, with the company expecting to generate approximately $3 million annually from this new revenue stream, alongside impressive profit margins of 25% to 30%.

This FDA approval not only boosts Citi Pharma's credibility but also positions the company as a growing global player, potentially attracting further investment and international partnerships.

Copyright Mettis Link News